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Akt/protein kinase B (PKB) functions in conserved signaling cascades that regulate growth and metabolism. In humans,
Akt/PKB is dysregulated in diabetes and cancer; in Caenorhabditis elegans, Akt/PKB functions in an insulin-like
signaling pathway to regulate larval development. To identify molecules that modulate C. elegans Akt/PKB signaling,
we performed a genetic screen for enhancers of the akt-1 mutant phenotype (eak). We report the analysis of three eak
genes. eak-6 and eak-5/sdf-9 encode protein tyrosine phosphatase homologs; eak-4 encodes a novel protein with an N-
myristoylation signal. All three genes are expressed primarily in the two endocrine XXX cells, and their predicted gene
products localize to the plasma membrane. Genetic evidence indicates that these proteins function in parallel to AKT-1
to inhibit the FoxO transcription factor DAF-16. These results define two membrane-associated protein tyrosine
phosphatase homologs that may potentiate C. elegans Akt/PKB signaling by cell autonomous and cell nonautonomous
mechanisms. Similar molecules may modulate Akt/PKB signaling in human endocrine tissues.
Citation: Hu PJ, Xu J, Ruvkun G (2006) Two membrane-associated tyrosine phosphatase homologs potentiate C. elegans AKT-1/PKB signaling. PLoS Genet 2(7): e99. DOI: 10.
1371/journal.pgen.0020099
Introduction
Conserved signaling cascades activated by insulin and
insulin-like growth factors (IGFs) are critical to the normal
development, growth, and physiology of many organisms. In
mice, insulin signaling regulates embryonic growth and
glucose uptake [1], and insulin-like growth factor-1 (IGF-1)
signaling regulates normal prenatal and postnatal growth [2].
Insulin-like signaling regulates cell size in Drosophila [3–5] and
development, metabolism, and longevity in Caenorhabditis
elegans [6–9].
In humans, dysregulation of insulin and IGF-1 signaling
plays a prominent role in disease pathogenesis. Patients with
type 2 diabetes mellitus exhibit resistance to insulin [10];
similar insulin resistance is observed in mice harboring
mutations in the insulin receptor and downstream compo-
nents of insulin signaling [11–14]. Downstream components
of IGF-1 signaling have been implicated in cancer patho-
genesis based on the identity of homologous transforming
retroviral oncoproteins [15,16] as well as the existence of gene
ampliﬁcations [17–19] and somatic mutations [20–23] in
primary tumors and tumor cell lines.
Binding of IGFs to their cognate transmembrane receptors
activates a cascade that is conserved throughout metazoan
phylogeny [24–26]. In C. elegans this pathway includes 38
insulin-like proteins [9,27], an insulin/IGF-1-receptor–like
molecule (DAF-2 [7]), PI 3-kinase catalytic (AGE-1 [28]) and
adaptor (AAP-1 [29]) subunits, a phosphoinositide-dependent
kinase (PDK-1 [30]), two Akt/protein kinase B (PKB) homologs
(AKT-1 and AKT-2 [31]), and a serum- and glucocorticoid-
inducible kinase homolog (SGK-1 [32]) (see later). Although
the biological role of most of the insulins has not been
established, a mutation in the daf-28 insulin gene causes
decreased insulin signaling [8], implicating DAF-28 as a
candidate ligand for DAF-2/InsR (insulin receptor homolog)
[9]. Additionally, the C. elegans INS-6 insulin can bind to and
activate the human InsR tyrosine kinase [33]. Analogous to
insulin and IGF-1 signaling in mammals [34,35], activation of
DAF-2/InsR leads to the phosphorylation, cytoplasmic reten-
tion, and inhibition of the FoxO transcription factor DAF-16
[36–40]. DAF-2/InsR signaling is likely downregulated by the
PTEN (phosphatase and tensin homolog) tumor suppressor
homolog DAF-18 [41–44].
daf-2/InsR mutants were ﬁrst identiﬁed based on their
increased tendency to enter an alternative larval develop-
mental stage called the dauer stage (daf refers to a dauer
formation phenotype) [45]. In replete growth conditions, C.
elegans undergoes four larval molts prior to reaching
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population density, high temperature, or starvation, early
larvae bypass the normal second and third larval stages and
instead develop into the alternative dauer larva. Dauers are
morphologically distinct from normal L3 larvae, exhibiting
radial and pharyngeal constriction, decreased pharyngeal
pumping, and cuticular specializations called alae. In addi-
tion, they increase intestinal fat storage and exhibit extended
longevity. Upon improvement of ambient conditions, dauers
recover to the L4 larval stage and proceed to reproductive
adulthood [47].
Genetic screens have deﬁned three signaling pathways that
normally function to inhibit dauer arrest under replete
environmental conditions [45,48–50]. In addition to DAF-2/
InsR inputs, dauer arrest is regulated by conserved DAF-7/
transforming growth factor (TGF)-b–like [51] and DAF-11/
guanylyl cyclase [52] signaling pathways. Insulin and TGF-b–
like ligands are expressed in small subsets of head neurons,
and this expression is regulated by various environmental
inputs and by cyclic guanosime monophosphate signaling
[9,27,51,53]. These ligands likely bind to cognate receptors
that are expressed widely in target tissues throughout the
animal [54]. The major targets of DAF-7/TGF-b signaling are
the SMAD4 tumor suppressor homolog DAF-3 [55] and its
binding partner DAF-5/SNO [56,57]. Mutations in daf-16/FoxO
speciﬁcally suppress dauer formation of daf-2/InsR pathway
mutants, indicating that DAF-16/FoxO is the major target of
DAF-2/InsR signaling in C. elegans [49,50]. Genetic analysis
indicates that these pathways function in parallel to promote
normal larval development [48,49].
Although many components of DAF-2/InsR signaling have
been characterized, at least three lines of evidence indicate
that undiscovered pathway components that act downstream
of DAF-2/InsR but parallel to AGE-1/PI3K may exist. Gain-of-
function mutations in pdk-1 and akt-1 suppress the dauer-
constitutive phenotype of age-1/PI3K null mutants more
efﬁciently than they do that of daf-2/InsR mutants [30,31].
The weak daf-18/PTEN(e1375) allele suppresses dauer arrest in
age-1/PI3K null mutants [42,43,49] but does not suppress the
dauer-constitutive phenotype of daf-2(e1370) mutants
[42,43,50]. Last, a functional DAF-16::GFP fusion protein
harboring point mutations in all four putative Akt/PKB
phosphorylation sites localizes to the nucleus but does not
increase life span or induce dauer formation in a daf-2 wild-
type background [38].
The tumor suppressor function of the 3-phosphoinositide
phosphatase PTEN [20,21], the frequent somatic mutation of
phosphatidylinositol (PI) 3-kinase in human cancers [23], and
the discovery of a germline Akt2 loss-of-function mutation in
a family with autosomal dominant insulin-resistant diabetes
[58] underscore the central role of this pathway in human
disease. In view of the striking structural and functional
conservation of insulin-like signaling throughout metazoan
phylogeny [59], it is likely that the identiﬁcation of novel
DAF-2/InsR signaling components will illuminate not only
mechanisms of developmental regulation in C. elegans but also
the pathogenesis of common human diseases such as cancer
and diabetes.
To identify genes encoding such molecules, we performed a
genetic screen for mutants that enhance the dauer-constit-
utive phenotype of an akt-1 null mutant (Eak screen). Seven
genetic loci enhance akt-1 when mutated; we report the
molecular identity of three eak loci here. These genes may
encode elements of a membrane-associated complex that
functions in two endocrine cells to potentiate insulin-like
signaling. A similar activity may modulate insulin and IGF-1
signals in human endocrine tissues.
Results
A Sensitized Genetic Screen for Akt/PKB Signaling
Components
We hypothesized that a genetic screen performed in a weak
dauer-constitutive daf-2/InsR pathway mutant background
might allow the identiﬁcation of DAF-2/InsR signaling
components which, when mutated alone, might not have
phenotypes. akt-1(mg306) was isolated in a genetic screen for
mutations that affect the production of or response to
elevated 3-phosphoinositide levels and contains a C!T
transition that generates a nonsense mutation in the
pleckstrin homology domain (see Materials and Methods).
In contrast to daf-2/InsR, age-1/PI3K, and pdk-1 loss-of-function
(lf) mutants, which form dauers at 25 8C or lower [28,30,60],
akt-1(lf) alleles have a Hid (high-temperature-induced dauer)
phenotype [61], developing reproductively at 25 8Cb u t
forming dauers at 27 8C (unpublished data and Figure 1).
Consistent with a role for AKT-1 in DAF-2/InsR signal
transduction [31,43], the 27 8C dauer-constitutive phenotype
of akt-1 mutants is suppressed by a daf-16/FoxO (lf) mutation
[61].
We mutagenized akt-1(mg306) animals and screened for
dauer arrest at 25 8C, a temperature at which akt-1(mg306)
mutants do not form dauers (Figure 1A). Among 30
independent mutants isolated from approximately 21,000
haploid genomes screened, 26 were suppressible by daf-16/
FoxO feeding RNAi (unpublished data), suggesting that their
dauer-constitutive phenotypes were either dependent upon
the presence of the akt-1(mg306) mutation or the result of
mutations in the daf-2/InsR pathway [49,50], or both. Twenty-
one of these 26 mutants were true Eak mutants, exhibiting
dauer arrest at 25 8C only in a homozygous akt-1(mg306)
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Synopsis
Insulin and insulin-like growth factor (IGF) signaling regulates critical
physiological processes in a wide variety of multicellular organisms.
In humans, dysregulation of IGF signaling underlies the patho-
genesis of cancer and diabetes. In the nematode Caenorhabditis
elegans, the DAF-2 insulin-like pathway regulates development,
metabolism, and longevity. All known components of DAF-2 insulin-
like signaling are structurally and functionally conserved in
mammals, suggesting that insights gained from studying this
pathway in C. elegans may shed light on pathogenetic mechanisms
underlying cancer and diabetes. In this study, the authors describe a
genetic screen designed to identify novel components of DAF-2
insulin-like signaling in C. elegans. They have characterized three
genes that may encode parts of a novel multimolecular membrane-
associated complex that potentiates DAF-2 insulin-like signaling in
two neuroendocrine cells, the XXX cells. Two of these genes encode
proteins similar to mammalian protein tyrosine phosphatases. These
results suggest that protein tyrosine phosphatase–like molecules
may transduce IGF signals in mammalian endocrine cells and
highlight the role of endocrine circuits in the pathogenesis of cancer
and diabetes.background (unpublished data and Figure 1A). Mapping and
complementation analysis indicate that these 21 mutants
deﬁne seven Eak genes.
All eak;akt-1(mg306) double mutants formed a high percent-
age of dauers at 25 8C (Figure 1A), exhibiting a dauer-
constitutive phenotype as strong as the canonical daf-2/InsR
mutant daf-2(e1370). However, in contrast to daf-2(e1370)
dauers, which have constricted pharynxes and dauer-speciﬁc
cuticular alae, all eak and eak;akt-1(mg306) dauers were partial
dauers, exhibiting characteristic alae but failing to undergo
pharyngeal remodeling (Figure S1). eak mutants also en-
hanced dauer arrest phenotypes of weak alleles of the daf-2/
InsR pathway components age-1/PI3K and pdk-1; whereas age-
1(hx546) and pdk-1(sa709) did not exhibit dauer arrest at 25 8C,
age-1;eak and eak;pdk-1 double mutants had strong dauer arrest
phenotypes at 25 8C (Figure S2A). Notably, eak mutants did
not enhance dauer arrest phenotypes of akt-2(ok393), a
deletion allele of akt-2 (Figure S2B). Therefore, eak gene
products may function in the same pathway as AKT-2.
In an akt-1(þ) background, eak mutants had minimal dauer-
constitutive phenotypes at 25 8C (Figure 1A) and relatively
weak dauer-constitutive phenotypes in comparison to akt-
1(mg306) animals at 27 8C (Figure 1B). The ability of eak
mutants to enhance dauer arrest phenotypes of age-1/PI3K,
akt-1, and pdk-1 loss-of-function mutants is consistent with
their functioning in a parallel pathway, and their low
penetrance dauer arrest phenotype at 25 8C would explain
why these mutants were not isolated in previous screens for
dauer arrest mutants performed at this temperature.
The eak Genes Act in the C. elegans Insulin-like Pathway
Loss-of-function mutations in daf-16/FoxO speciﬁcally sup-
press the dauer arrest phenotype of daf-2/InsR pathway
mutants [49,50]. To determine whether eak gene products
function in the daf-2/InsR pathway, we performed epistasis
analysis on daf-16;eak double mutants and daf-16;eak;akt-1
triple mutants. For epistasis analysis of eak-6(mg329), we used
feeding RNAi of daf-16/FoxO; close linkage of eak-6 and daf-16
on Chromosome I prevented construction of an eak-6 daf-16
Figure 1. Dauer Formation Phenotypes of eak Mutants
eak single mutants, eak-x;eak-y double mutants, or eak;akt-1 double mutants were assayed for dauer arrest at (A) 25 8C and (B) 27 8C. (C) eak 27 8C dauer
arrest phenotypes are suppressed by a mutation in daf-16/FoxO. (D) akt-1, eak-4, and eak-6 27 8C dauer arrest phenotypes are suppressed by RNAi of
daf-16/FoxO and daf-12/NHR. All error bars indicate standard deviation. All experiments were performed three times. Refer to Table S1 for numbers of
animals scored. eak-5 is allelic to the synthetic dauer formation gene sdf-9 [62] and is referred to as sdf-9 throughout the paper. Mutant alleles used were
daf-2(e1370), akt-1(mg306), eak-4(mg348), sdf-9(mg337) and sdf-9(ut187), eak-6(mg329), and daf-16(mgDf47). sdf-9(ut187) was used to construct the
eak-4;sdf-9, eak-6;sdf-9, and daf-16;sdf-9 double mutants. Multiple alleles of eak-4 and sdf-9 yielded phenotypes similar to those shown. See Table S1 for
numbers of animals assayed.
DOI: 10.1371/journal.pgen.0020099.g001
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suppressed dauer-constitutive phenotypes of all eak single
mutants tested (Figure 1C) and both eak;akt-1 double mutants
tested (Figure S3A), whereas a daf-3/SMAD null mutation did
not [62]. RNAi of daf-16/FoxO also suppressed akt-1(mg306), eak-
4(mg348), and eak-6(mg329) dauer-constitutive phenotypes, as
did RNAi of the nuclear hormone receptor gene daf-12
(Figure 1D; loss-of-function daf-12 mutations suppress dauer
arrest caused by most known dauer-constitutive mutants
[48,50,61,63–65]). These ﬁndings suggest that eak genes
function in the daf-2/InsR pathway.
To help determine whether eak gene products function in
parallel to AKT-1, we constructed eak;daf-18 and eak;akt-1
gain-of-function double mutants and performed epistasis
analysis. The weak daf-18/PTEN allele e1375 suppresses dauer
arrest in age-1/PI3K null mutants but does not suppress dauer
arrest in daf-2(e1370) [42,43,49,50], and the akt-1 gain-of-
function allele mg144 exhibits stronger suppression of age-1/
PI3K null phenotypes than daf-2/InsR loss-of-function pheno-
types [31], suggesting that DAF-18/PTEN and AKT-1 function
in an AGE-1/PI3K–speciﬁc branch of DAF-2/InsR outputs. An
inability of daf-18(e1375) or akt-1(mg144) to suppress eak dauer
arrest would indicate that eak gene products function in
parallel to and independently of AGE-1/PI3K. Both daf-
18(e1375) and akt-1(mg144) strongly suppressed dauer arrest
in eak-4, eak-5/sdf-9, and eak-6 mutants (Figure S3B and S3C),
suggesting that eak gene products function either upstream of
or in parallel to AGE-1/PI3K and AKT-1.
To address the issue of whether all three eak gene products
function in the same pathway, we constructed eak-x;eak-y
double mutants and tested them for dauer arrest at 25 8C and
27 8C. Lack of enhanced dauer arrest in double mutants
would suggest that eak gene products function together in the
same complex or pathway. eak-4;sdf-9 and eak-6;sdf-9 double
mutants did not arrest as dauers at 25 8C (Figure 1A) and did
not exhibit enhanced dauer arrest at 27 8C (Figure 1B),
indicating that the EAK proteins likely function together in
the same complex or pathway.
Most dauer-constitutive mutants in the daf-2/InsR pathway
also have extended organismal longevity [6,29,30,66]. There-
fore, we performed longevity assays on all eak mutants.
Consistent with a recent report [32], the akt-1(mg306)
mutation extended median life span by less than 10%, which
is a smaller extension of life span than has been seen with
other loss-of-function dauer-constitutive mutants in the daf-2/
InsR pathway. Interestingly, no eak mutants tested extended
median or maximum life span signiﬁcantly (Figure S4).
Furthermore, eak alleles did not enhance life span extension
of akt-1(mg306), although they all strongly enhanced the dauer
formation phenotype of akt-1(mg306) (Figure 1A). Thus, eak
signaling does not subserve longevity control.
Two eak Genes Are Related to Protein Tyrosine
Phosphatases
Nine mutants deﬁne the eak-5 gene. Single nucleotide
polymorphism (SNP) mapping [67] localized eak-5 to an
approximately 480-kb genomic interval between cosmid
F48F5 and the right telomere of Chromosome V. sdf-9,
identiﬁed in a screen for enhancers of the dauer-constitutive
phenotype of unc-31(e169) [62], lies within this interval.
Sequencing of sdf-9 exons and splice junctions in all nine
eak-5 alleles identiﬁed eight distinct point mutations (Table
1), and an akt-1 sdf-9 double mutant constructed using the sdf-
9(ut187) allele identiﬁed in the unc-31(e169) enhancer screen
[62] had a strong dauer-constitutive phenotype at 25 8C
(Figure 1A), indicating that eak-5 is allelic to sdf-9.
The eak-6 gene is deﬁned by one allele, mg329.S N P
mapping localized eak-6(mg329) to an approximately 210-kb
genomic region on Chromosome I between cosmids F52F12
and B0379. BLASTP analysis of SDF-9 against the C. elegans
Wormpep database (http://www.sanger.ac.uk/Projects/
C_elegans/WORMBASE/current/wormpep.shtml) identiﬁed
a predicted homolog encoded by open reading frame
F10G8.4. This open reading frame lies within the eak-6
genomic interval deﬁned by our SNP mapping. Sequencing
of predicted exons and splice junctions of F10G8.4 in eak-
6(mg329) identiﬁed a G!A transition resulting in an opal
nonsense mutation near the predicted amino-terminus of the
protein (Figure 2A). Two of nine transgenic lines containing a
genomic PCR fragment including the putative promoter,
open reading frame, and 3’ untranslated regions (UTR) of
F10G8.4 exhibited rescue of the dauer arrest phenotype of an
eak-6(mg329);akt-1(mg306) double mutant (unpublished data),
supporting the argument that F10G8.4 is eak-6.
EAK-6 and SDF-9 both have amino acid similarity to PTPs
(Figure 2B and [62]). Conservation is strongest in the ten
motifs that are conserved among 37 human PTPs [68].
Whereas SDF-9 does not retain the canonical catalytic
cysteine residue found in all known PTPs and is therefore
predicted to be catalytically inactive [62,69], the catalytic
cysteine is conserved in EAK-6. Despite this difference, sdf-9
and eak-6 mutants have a similar phenotype (Figure 1A and
1B). Among 19 amino acid residues that are invariant among
113 vertebrate PTPs [68], 15 are conserved in EAK-6 and 13
are conserved in SDF-9 (Figure 2B). PTP activity assays on
both epitope-tagged EAK-6 expressed in and immunopreci-
pitated from cultured human cells and a GST-EAK-6 fusion
protein expressed in Escherichia coli revealed no hydrolytic
activity on the substrate p-nitro-phenylphosphate (PNPP), a
phosphotyrosine analog (unpublished data). Thus, EAK-6 and
SDF-9 may be inactive phosphatase homologs that bind to
tyrosine phosphoproteins. However, we cannot rule out the
possibility that EAK-6 has PTP activity that is not detectable
in the PNPP assay.
Table 1. eak-5 Is Allelic to the Synthetic Dauer Formation Gene
sdf-9
eak-5 Allele sdf-9 Mutation Predicted Change
mg324 G(17090)!A G129R
mg325 C(17890)!T P219S
mg330 C(17879)!T P215L
mg336 G(17694)!A G168E
mg337 G(16207)!A First exon splice donor mutation
mg341 C(17879)!T P215L
mg342 G(16113)!A Promoter mutation
mg343 G(17912)!A G226E
mg349 C(17121)!T A139V
sdf-9 residues mutated in each eak-5 allele are numbered according to the annotated
sequence of YAC Y44A6D (http://www.ncbi.nlm.nih.gov/entrez/viewer.
fcgi?db¼nucleotide&val¼3217937). Predicted amino acid changes are numbered accord-
ing to the predicted primary sequence of SDF-9 [62].
DOI: 10.1371/journal.pgen.0020099.t001
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Signal
Three alleles, mg326, mg328, and mg348, deﬁne the eak-4
locus. SNP mapping narrowed the eak-4 interval to an
approximately 560-kb genomic region on Chromosome IV
between cosmids B0001 and T23B5. Cosmid rescue assays
identiﬁed F53B2 as the rescuing cosmid, and rescue experi-
ments with genomic PCR fragments corresponding to
Figure 2. Predicted Primary Amino Acid Sequence of EAK-6 and Similarity with PTPs
(A) EAK-6 amino acid sequence. EAK-6 sequence was derived from full-length cDNA amplified by RT-PCR from wild-type C. elegans total RNA. The PTP
domain is denoted in boldface. The residue mutated in eak-6(mg329) is boxed and the predicted change indicated above the mutated residue. Amino
acids encoded by an alternatively spliced exon present in EAK-6L but not in EAK-6S (see Materials and Methods) are underlined.
(B) EAK-6 homology with PTPs. The PTP domain of EAK-6 is aligned with that of SDF-9 and 3 human PTPs. Sequences used in the alignment are based
on domains defined by Pfam [101] and correspond to amino acids 40 to 276 of PTPN1 (PTP1B), 57 to 308 of EAK-6, 31 to 283 of SDF-9, 265 to 500 of
PTPRA (receptor-type PTPa), and 273 to 520 of PTPN11 (SHP-2). Alignment was performed using ClustalX 1.8 and MacBoxshade 2.15. Conserved and
identical residues are shaded. Ten motifs conserved among 37 vertebrate PTPs [68] are underlined, and 19 residues that are invariant among 113
vertebrate PTP domains are boxed. The four invariant residues that are not identical in EAK-6 (R45, Q85, H214, and G220, numbered according to the
PTPN1 primary sequence) are denoted with dots. The catalytic cysteine residue [69] is denoted by an asterisk. Two conserved residues that are not
conserved in EAK-6, D181 and Q262, are denoted by arrowheads.
DOI: 10.1371/journal.pgen.0020099.g002
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F53B2.3 as a candidate gene for eak-4.S e q u e n c i n go f
predicted exons and splice junctions in F53B2.3 identiﬁed
independent point mutations in all three eak-4 alleles (Figure
3). RT-PCR of wild-type C. elegans total RNA conﬁrmed the
WormBase (WormBase Web site, http://www.wormbase.org,
release WS120, March 1, 2004) predicted mRNA structure. A
PCR fragment containing the predicted F53B2.3 promoter,
open reading frame, and 3’ UTR rescued the eak-4 mutant
phenotype in one of one transgenic line, further supporting
the conclusion that F53B2.3 is eak-4.
EAK-4 has amino acid similarity to four other C. elegans
proteins, denoted by cosmid gene names F14H8.2, F14H8.4,
F14H8.5, and T19C3.7 (Figure 3). The function of these
proteins is not known. A glycine residue that is conserved
among EAK-4, F14H8.2, F14H8.4, and F14H8.5 is mutated in
mg348, which is the strongest eak-4 allele based upon the 20 8C
dauer-constitutive phenotype of eak-4;akt-1 double mutants
(unpublished data). A heteroallelic strain with eak-4(mg348) in
trans to a deﬁciency did not exhibit enhanced dauer arrest
(Figure S5), suggesting that eak-4(mg348) is a null allele.
Notably, EAK-4, F14H8.2, F14H8.4, and F14H8.5 all have
canonical N-myristoylation sequences [70], suggesting that
they may associate with membranes.
eak Promoters Drive Transcription Specifically in the
XXXL/R Cells
A functional SDF-9::GFP fusion protein is expressed
speciﬁcally in the XXXL/R cells [62]. Promoter fusions of
eak-4 and eak-6 to GFP [71] were speciﬁcally expressed in two
cells in the head that we identiﬁed as the XXXL/R cells based
on their variable positions and neurite-like morphology [62].
Most eak-6p::GFP-containing animals also exhibited GFP
expression in a third cell identiﬁed as the pharyngeal M1
motor neuron based on the position of its cell body and
axonal process [72].
To conﬁrm this result, we constructed an sdf-9 promoter
fusion to red ﬂuorescent protein [73], coinjected either eak-
4p::GFP or eak-6p::GFP with sdf-9p::RFP, and assayed for
colocalization of GFP and RFP in transgenic animals. The
sdf-9p::RFP fusion was expressed exclusively in two head cells
with position and morphology consistent with their identi-
ﬁcation as the XXX cells [62]. In both strains containing GFP
and RFP reporter constructs, GFP and RFP colocalized
(Figure 4A), indicating that eak-4, sdf-9, and eak-6 are all
expressed in XXXL/R.
EAK-4, SDF-9, and EAK-6::GFP Fusion Proteins Localize to
the Plasma Membrane
In order to visualize the subcellular localization of EAK
proteins, we made full-length translational GFP fusion
constructs and expressed them in wild-type animals. Both
EAK-4::GFP and EAK-6::GFP fusion proteins were expressed
speciﬁcally in XXX, as was an SDF-9::GFP fusion protein [62].
They were also variably expressed in the intestine (unpub-
lished data), a common site of artifactual GFP expression
[74,75]. Coexpression of translational GFP fusions with an sdf-
9p::RFP promoter fusion indicated that all three GFP fusions
localize to the plasma membrane of the XXX cells (Figure 4B).
Membrane localization was also apparent in intestinal cells
(unpublished data).
We determined the role of the N-myristoylation consensus
motif in EAK-4 plasma membrane localization by construct-
ing an EAK-4::GFP mutant in which the invariant glycine
residue at position 2 is mutated to alanine (G2A). In contrast
to wild-type EAK-4::GFP, which was localized to the plasma
membrane (Figure 4B and 4C), the EAK-4 G2A mutant GFP
fusion protein exhibited diffuse cytoplasmic localization
(Figure 4C), indicating that an intact N-myristoylation motif
is required for EAK-4 plasma membrane localization.
To gain insight into the inﬂuence of DAF-2/InsR signaling
on EAK plasma membrane localization, we examined SDF-
9::GFP subcellular localization in daf-2(e1370) mutant animals
grown at 25 8C. At this temperature, daf-2(e1370) animals
undergo dauer arrest (Figure 1A). SDF-9::GFP exhibited
plasma membrane localization in both wild-type and daf-
2(e1370) animals (Figure S6), indicating that its localization
does not require normal levels of DAF-2/InsR signaling.
Expression of AKT-1::GFP in XXXL/R Rescues Dauer Arrest
in an eak-4;akt-1 Double Mutant
In stark contrast to the speciﬁc expression of EAK::GFP
proteins in the XXX cells (Figure 4A and 4B), a functional
AKT-1::GFP fusion protein is expressed widely in postem-
Figure 3. EAK-4 Amino Acid Sequence and Alignment with Four C.
elegans Homologs
Sequences represent the entire predicted amino acid sequences of all
five genes. EAK-4 sequence was derived from full-length cDNA amplified
by RT-PCR from wild-type C. elegans total RNA. Alignment was
constructed using ClustalX 1.8 and MacBoxshade 2.15. Shaded residues
indicate amino acid identity and conservation. Mutated residues in three
alleles of eak-4 are boxed, and the predicted amino acid change is
indicated above the box. The conserved G at residue 2 and S/T/A (boxed)
at residue 6 in the N-myristoylation consensus sequence [70] are
denoted by an asterisk and a vertical arrow, respectively.
DOI: 10.1371/journal.pgen.0020099.g003
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function speciﬁcally in XXXL/R, we expressed the akt-1 open
reading frame and 3’ UTR under the control of the eak-4
promoter and asked whether this transgene could rescue
dauer arrest in an eak-4(mg326);akt-1(mg306) double mutant. In
three of three transgenic lines assayed, animals harboring the
eak-4p::AKT-1 transgene bypassed dauer arrest and grew
reproductively, whereas nontransgenic siblings formed da-
uers (Figure 5). Control transgenic animals expressing an eak-
4p::GFP transcriptional fusion construct did not bypass dauer
(unpublished data). These results show that AKT-1 expression
in the XXX cells is sufﬁcient to rescue the akt-1(mg306) dauer
arrest phenotype and indicate that the XXX cells are a major
site of AKT-1 function in C. elegans.
A DAF-16A::GFP Fusion Protein Is Not Expressed in XXXL/R
In order to assess whether eak gene products regulate DAF-
16/FoxO cell autonomously, we ﬁrst determined whether a
functional DAF-16A::GFP fusion protein under the control of
the daf-16a promoter is expressed in XXXL/R. We constructed
a strain harboring integrated DAF-16A::GFP and sdf-9p::RFP
transgenes and assayed for colocalization of GFP and RFP.
Figure 4. EAK-4, SDF-9, and EAK-6 Localize to the Plasma Membrane of the XXX Cells
(A) eak-4, sdf-9, and eak-6 promoters drive expression in the same cells. Wild-type animals harboring an extrachromosomal array with eakp::GFP and sdf-
9p::RFP constructs were analyzed by fluorescence microscopy. Representative photographs are shown. Animals are oriented anterior left and dorsal up.
(B) EAK-4::GFP, SDF-9::GFP, and EAK-6::GFP fusion proteins localize to the plasma membrane of XXX. Animals harboring EAK::GFP translational fusion
constructs and an integrated sdf-9p::RFP array were analyzed using fluorescence microscopy. Representative photographs of a XXX cell are shown.
(C) Mutation of the invariant glycine in the N-myristoylation motif of EAK-4 abrogates plasma membrane localization. Animals harboring either a wild-
type EAK-4::GFP construct or an EAK-4::GFP construct with the glycine at position 2 mutated to alanine (G2A) were analyzed using fluorescence
microscopy.
DOI: 10.1371/journal.pgen.0020099.g004
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it did not colocalize with RFP (Figure 6), indicating that it is
not expressed at high levels in XXXL/R. Therefore, eak gene
products may regulate DAF-16/FoxO nonautonomously.
Discussion
We have used an akt-1 enhancer screen to identify three
genes encoding proteins that potentiate AKT-1 signaling. It is
noteworthy that this screen has yielded neither weak alleles of
known dauer-constitutive genes encoding components of
DAF-2/InsR, DAF-7/TGF-b, or DAF-11/GC pathways nor
strong alleles of the many mutants with weak dauer-
constitutive phenotypes [61,63,76]. The fact that we have
isolated multiple alleles of ﬁve of the seven genes identiﬁed in
our screen (Figure 3, Table 1, and unpublished data) without
identifying alleles of most mutants with weak dauer pheno-
types argues that the target for akt-1 enhancement is very
speciﬁc and that most mutants with weak dauer phenotypes
do not strongly enhance akt-1(mg306). Therefore, eak-4, sdf-9,
and eak-6 likely do not enhance akt-1(mg306) simply by virtue
of their weak dauer-constitutive phenotype; rather, these
genes probably encode components of a complex or pathway
that cooperates speciﬁcally with AKT-1.
sdf-9 was also identiﬁed in a genetic enhancer screen using
the weak dauer arrest mutant unc-31(e169) as a genetic
background [62]. unc-31 encodes a homolog of CAPS, a
protein required for calcium-induced dense core vesicle
exocytosis [77]. Since insulin is stored in and secreted from
dense core vesicles in pancreatic islet beta cells [78], it is likely
that UNC-31/CAPS and AKT-1 function in the same insulin
signaling pathway. This is underscored by the suppression of
the weak dauer arrest phenotypes of akt-1 and unc-31 mutants
by daf-16/FoxO mutations (Figure 1C and 1D [61]) and may
explain why sdf-9 mutants were isolated in both screens. akt-1
sdf-9 and unc-31;sdf-9 double mutants have similar dauer arrest
phenotypes at 25 8C (Figure 1A and [62]).
Surprisingly, we have not identiﬁed any akt-2 mutants in
this screen. We expected akt-2 mutants to emerge from this
screen, given that akt-1;akt-2 double mutants [79] as well as
animals subjected to simultaneous RNAi of akt-1 and akt-2
[31,32] undergo dauer arrest. Furthermore, eak mutants do
not enhance dauer arrest of akt-2 mutants (Figure S2B),
indicating that they may act in the same pathway. However,
none of the 21 alleles isolated in the Eak screen is X-linked
(the akt-2 gene lies on the X chromosome). In the course of
constructing an akt-1(mg306);akt-2(ok393) double mutant, we
noted that akt-1;akt-2 animals formed nonconditional dauers
in the F3 generation but were maternally rescued for dauer
arrest in the F2 generation (unpublished data), explaining
why akt-2 alleles were not isolated in this F2 screen. It is
possible that other components of DAF-2/InsR signaling
would emerge from an F3 akt-1 enhancer screen.
In contrast to previous results demonstrating a strong
dauer arrest phenotype for multiple sdf-9 alleles [62], we have
only observed weak dauer phenotypes for all eak-4, sdf-9, and
eak-6 alleles tested (Figure 1 and unpublished data). The
alleles tested included the ut163 and ut187 alleles of sdf-9
previously described (Figure 1A and 1B; [62]). As dauer assays
at 27 8C are exquisitely sensitive to small changes in
environmental conditions [63], we attribute these differences
to small discrepancies between assay conditions in different
laboratories. This may also explain the disparate effects of
XXX laser ablation on dauer formation reported in the
literature [62,65,80].
The XXX Cells as a Site of DAF-2/InsR Function
The XXX cells are annotated as hypodermal cells in the
head [81] that abut the pseudocoelom and have neuronal
characteristics [62,80,82]. Laser ablation of the XXX cells
causes partial dauer arrest [62], indicating that the XXX cells
normally function to inhibit dauer arrest. The speciﬁc
expression of EAK-4, SDF-9, and EAK-6 in the XXX cells
(Figure 4), taken together with our ﬁnding that AKT-1
expression in XXX sufﬁces to rescue the dauer arrest
phenotype of an eak-4;akt-1 double mutant (Figure 5),
indicates that the XXX cells may be a major site of DAF-2/
InsR function in C. elegans. However, the output of the XXX
cell in the regulation of dauer arrest also depends on insulin
signaling in other cells, since the dauer arrest phenotype
caused by ablation of the XXX cells is suppressed by
mutations in daf-16/FoxO but not by mutations in daf-3/SMAD4
[62], This is also consistent with our observation that DAF-
16::GFP expressed from the daf-16a promoter is not expressed
in XXX (Figure 6). It is not known whether DAF-2/InsR is
expressed in XXX.
As reported previously for sdf-9 [62], we have observed that
eak-4, sdf-9, and eak-6 single mutants form partial dauers that
have cuticular alae but have not undergone pharyngeal
remodeling (Figure S1). Indeed, some daf-2/InsR mutant
alleles also cause partial dauer arrest [60]. It is possible that
signals from the XXX cells control dauer arrest and
extrapharyngeal remodeling, whereas DAF-2/InsR signaling
outputs from other cells, for example, the pharyngeal tissues
themselves, may affect pharyngeal remodeling. Phenotypes of
rare daf-2 mosaics that lack daf-2 activity in both XXX cells
and various portions of the ABa cell lineage [83] suggest that
descendants of the ABalpa cell may regulate pharyngeal
remodeling during dauer formation.
Figure 5. Expression of AKT-1 in XXX is Sufficient to Rescue the 25 8C
Dauer Phenotype of an eak-4;akt-1 Double Mutant
eak-4(mg326);akt-1(mg306) double mutant animals carry a transgene
containing the akt-1 genomic region and 3’ untranslated region under
the control of the eak-4 promoter. Three independent lines rescue eak-
4(mg326);akt-1(mg306) dauer arrest at 25 8C. Error bars indicate standard
deviation. This experiment was performed twice. Refer to Table S1 for
numbers of animals scored.
DOI: 10.1371/journal.pgen.0020099.g005
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DAF-2/InsR Signaling
Enhancement of akt-1 phenotypes could occur either
through further attenuation of DAF-2/InsR signaling or by
derangement of DAF-7/TGF-b or DAF-11/GC signaling [36].
As is the case for all known components of the DAF-2/InsR
pathway [30–32, 48, 49], eak-4, sdf-9, and eak-6 phenotypes are
fully suppressed by mutations in daf-16/FoxO (Figure 1C and
1D [62]), the major target of DAF-2/InsR signaling [37,49].
This supports the contention that EAK-4, SDF-9, and EAK-6
are components of DAF-2/InsR signaling. Indeed, the strong,
nonconditional dauer phenotype of some eak;akt-1 double
mutants (unpublished data) is reminiscent of the phenotype
of strong loss-of-function alleles of daf-2/InsR [60].
Results of epistasis experiments with the weak daf-18/PTEN
allele e1375 [42,43] and the akt-1 gain-of-function allele mg144
[31] (Figure S3B and S3C) implicate EAK-4, SDF-9, and EAK-6
function upstream of or in parallel to AGE-1/PI3K and AKT-
1. Since one of the molecular consequences of either DAF-18/
PTEN loss-of-function or AKT-1 gain-of-function is phos-
phorylation and inhibition of DAF-16/FoxO [38–40], it is not
surprising that daf-18(e1375), akt-1(mg144), and daf-16(mgDf47)
are all epistatic to eak mutants.
EAK Proteins May Inhibit DAF-16/FoxO Nonautonomously
eak-4, sdf-9, and eak-6 mutants strongly enhance the akt-1
null phenotype (Figure 1A), suggesting that EAK proteins
function in parallel to AKT-1. In addition, eak-4;sdf-9 and eak-
6;sdf-9 double mutants do not exhibit more severe phenotypes
compared to the respective single mutants (Figure 1A and
1B), indicating that EAK-4, SDF-9, and EAK-6 function in the
same pathway or complex. Parallel signaling of AKT-1 and
EAK proteins could occur either at the organismal level,
whereby AKT-1 signaling in non-XXX cells would converge
with EAK signals in XXX to inhibit DAF-16/FoxO cell
nonautonomously, or at the intracellular level, whereby
AKT-1 signaling would converge with EAK signals in XXX
to inhibit DAF-16/FoxO cell autonomously. The ability of
AKT-1 expressed speciﬁcally in XXX to rescue an eak-4;akt-1
double mutant (Figure 5) supports the notion that AKT-1
functions at least in part by signaling in parallel to EAK-4,
SDF-9, and EAK-6 in XXX. However, the observation that
dauer arrest caused by XXX laser ablation is suppressed by a
daf-16 loss-of-function mutant [62] and the lack of DAF-
16A::GFP expression in XXX (Figure 6) suggest that EAK
proteins regulate DAF-16A nonautonomously. It is possible
that AKT-1 phosphorylates critical substrates in XXX distinct
from DAF-16/FoxO. Alternatively, since there are at least
three DAF-16/FoxO isoforms that may be transcribed from
distinct promoters (WormBase Web site, http://www.
wormbase.org, release WS150, November 30, 2005), a DAF-
16/FoxO isoform distinct from DAF-16A may be a target of
AKT-1 and EAK signals in XXX.
Mechanisms of SDF-9 and EAK-6 Membrane Localization
In contrast to EAK-4, which likely localizes to the plasma
membrane through N-myristoylation (Figure 4C), the mech-
anisms underlying the membrane localization of SDF-9 and
EAK-6 are not clear. Neither SDF-9 nor EAK-6 possesses an
N-myristoylation motif or a predicted transmembrane
domain. SDF-9 and EAK-6 could associate with the plasma
membrane by binding to membrane-associated proteins such
as EAK-4. Alternatively, given that SDF-9 (and possibly EAK-
6) has an inactive PTP domain that might bind to
phosphotyrosine residues, they could bind to membrane-
associated tyrosine phosphoproteins such as DAF-2/InsR. The
ability of the DAF-18 ortholog PTEN to hydrolyze both
phosphotyrosine [84] and phosphoinositides [85] suggests a
third possible mechanism of SDF-9 and EAK-6 membrane
localization via direct binding to phospholipids.
We addressed each model experimentally. First, coprecipi-
tation assays on N-terminal epitope-tagged EAK-4, SDF-9,
and EAK-6 expressed in all pairwise combinations in cultured
293T cells failed to reveal direct physical interactions among
the three proteins despite high levels of protein expression
(unpublished data). Furthermore, epitope-tagged SDF-9 and
EAK-6 did not coprecipitate tyrosine phosphoproteins after
exposure of transfected cultured 293T cells to IGF-1
(unpublished data). Finally, radiolabeled SDF-9 and EAK-6
synthesized in vitro did not bind to phosphoinositides
immobilized on nitrocellulose (Seth Field and Lewis Cantley,
personal communication). The observation that SDF-9::GFP
exhibits plasma membrane localization in the absence of
intact DAF-2/InsR signaling (Figure S6) is consistent with the
lack of SDF-9 binding to tyrosine phosphoproteins in 293T
cells and suggests that SDF-9 membrane association is
independent of tyrosine phosphorylation. We cannot rule
out the possibility that biologically relevant EAK protein-
protein or protein-lipid interactions require additional
components that exist in vivo but were not present in the
assays described. Notably, one (or more) of the four eak genes
that remain to be cloned (eak-1, eak-2, eak-3, and eak-7) may
encode such a molecule.
SDF-9 and EAK-6 Are Similar to Tyrosine Phosphatases
The similarity of SDF-9 and EAK-6 amino acid sequences to
PTPs (Figure 2B and [62]) suggests that SDF-9 and EAK-6 may
comprise a PTP that activates downstream signaling through
dephosphorylation of tyrosine residues. Although SDF-9 lacks
the cysteine residue that is critical for PTP catalytic activity
[69], EAK-6 retains this cysteine (Figure 2B) and may possess
phosphatase activity. Many receptor-type PTPs harbor
Figure 6. A Functional DAF-16A::GFP Fusion Protein Is Not Expressed in
XXX
Wild-type animals harboring integrated DAF-16A::GFP and sdf-9p::RFP
arrays were analyzed by confocal microscopy. Representative photo-
graphs of a single animal are shown. The animal is oriented anterior left
and dorsal up. Merging of GFP and RFP images reveals no colocalization
of fluorescent proteins.
DOI: 10.1371/journal.pgen.0020099.g006
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have PTP activity [68]. Similarly, SDF-9 and EAK-6 might
function as a heteromeric PTP associated with the plasma
membrane. The ﬁnding that EAK-6 expressed in mammalian
cells or bacteria lacks PTP activity on the substrate PNPP
does not preclude the possibility that it may have activity on
speciﬁc phosphotyrosine residues in the context of a full-
length protein.
Alternatively, it is possible that EAK-6 has phosphohydro-
lase activity on nonphosphotyrosine or nonprotein sub-
strates. Among 19 invariant residues in the catalytic
domains of 113 vertebrate PTPs [68], 15 are conserved in
EAK-6 (Figure 2B). Two of the four invariant residues not
conserved in EAK-6, R45 and G220 (PTPN1/PTP1B number-
ing), are thought to be involved in phosphotyrosine binding
[68]. In EAK-6 these are replaced with isoleucine and alanine,
respectively. Changes in these residues could reﬂect changes
in EAK-6 substrate speciﬁcity.
A third possibility is that EAK-6 does not possess catalytic
activity. One of the four invariant residues not conserved in
EAK-6, H214, is a glutamine residue in EAK-6 (Figure 2B).
This histidine is proposed to lower the pKa of the catalytic
cysteine [68]; mutation of H214 to alanine reduces the
catalytic activity of PTPN1/PTP1B approximately 80-fold
[86]. Two other conserved residues, D181 and Q262, are
replaced by glutamate and leucine, respectively, in EAK-6
Figure 7. Models of EAK-4, SDF-9, and EAK-6 Function
(A) Cell autonomous signaling in XXX. A schematic of one XXX cell is shown. EAK proteins function in parallel with AKT-1 and in the same pathway as
AKT-2 to promote nondauer development by potentiating DAF-9/CYP27A1 function either directly or indirectly. DAF-9/CYP27A1 synthesizes 3-keto-
7(5a)-cholestenoic acid, a ligand that promotes reproductive development by inhibiting the nuclear hormone receptor DAF-12 [91]. DAF-16/FoxO is
denoted with dashed lines, since DAF-16A does not appear to be expressed in XXX. It is not known whether other DAF-16/FoxO isoforms or DAF-2/InsR
are expressed in XXX.
(B) Nonautonomous signaling from XXX. A schematic of the anterior portion of an animal is shown with the head pointing left. The pharynx is also
shown. XXX cells are denoted by red ovals, and DAF-16/FoxO-expressing cells are denoted by green ovals. EAK proteins in the XXX cells generate
signals that regulate the synthesis or secretion of a hormone that inhibits DAF-16/FoxO function in other cells.
DOI: 10.1371/journal.pgen.0020099.g007
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PTP Homologs Potentiate Akt Signaling(Figure 2B); D181E and Q262A mutations reduce PTPN1/
PTP1B catalytic activity approximately 600-fold and approx-
imately 80-fold, respectively [86]. Interestingly, the PTPN1/
PTP1B H214A mutation reduces Km approximately 5-fold,
and the D181E and Q262A mutations reduce Km approx-
imately 10-fold each [86]. Therefore, although substitutions in
these conserved residues in EAK-6 may decrease hydrolytic
activity, they also may increase binding afﬁnity for substrate.
These data are consistent with a model of EAK-6 and SDF-9
functioning as inactive PTP domains that bind to tyrosine
phosphoproteins and regulate their interactions with other
proteins in a manner similar to STYX family proteins [87]. In
this scenario, EAK-6 and SDF-9 could also potentiate DAF-2/
InsR signaling by serving as adaptor proteins that increase the
local concentration of associated proteins during cascade
activation. Resolution of these uncertainties awaits a more
detailed analysis of EAK-6 catalytic activity, binding to
tyrosine phosphoproteins, and structure.
Bifurcation of DAF-2/InsR Signaling into Dauer and
Longevity Outputs
Temporal and spatial speciﬁcity of DAF-2/InsR signaling
may underlie differential effects on dauer formation and
longevity. Inhibition of DAF-2/InsR signaling during early
development enhances dauer formation but has no effect on
organismal longevity, and inhibition of DAF-2/InsR signaling
in early adulthood is sufﬁcient to extend life span [88]. eak-4,
sdf-9, and eak-6 promoter and translational fusions are all
expressed continuously from late embryogenesis through
early adulthood (unpublished data and [62]); thus, temporal
regulation of EAK-4, SDF-9, and EAK-6 expression is not
likely to explain the normal life span of eak-4, sdf-9, and eak-6
mutants. The speciﬁcity of eak-4, sdf-9, and eak-6 expression in
XXX suggests that DAF-2/InsR signaling in the XXX cells may
have speciﬁc dauer regulatory functions that have no impact
on organismal longevity. This model is supported by a recent
analysis of tissue-speciﬁc functions of DAF-16/FoxO indicat-
ing that longevity is primarily regulated by intestinal DAF-16/
FoxO, whereas dauer arrest is regulated by neuronal DAF-16/
FoxO [89]. Similarly, neuronal DAF-2/InsR regulates life span,
whereas intestinal DAF-2/InsR controls metabolism [90]. In
light of the observation that DAF-16A::GFP is not expressed
in XXX (Figure 6), it will be of great interest to determine
whether DAF-16A::GFP localizes to the nucleus in eak;akt-1
double mutants and, if so, whether there is tissue-speciﬁcity
of nuclear localization.
A Model for EAK Protein Function
The data presented in this work are consistent with a model
whereby EAK-4, SDF-9, and EAK-6 function in a single
complex or pathway at the XXX plasma membrane in parallel
with AKT-1 to inhibit dauer formation. Overexpression of
the steroid hydroxylase DAF-9/CYP27A1, which is normally
expressed in XXX, suppresses dauer arrest in sdf-9 mutants
[62], suggesting that DAF-9 functions downstream of or
parallel to SDF-9. In XXX, SDF-9 may function with DAF-9/
CYP27A1 to promote the synthesis and/or secretion of
dafachronic acids, which are high-afﬁnity ligands for the
nuclear hormone receptor DAF-12 [62,91]. Therefore, high
EAK protein activity may inhibit dauer formation by
potentiating DAF-9/CYP27A1 activity, either directly or
indirectly (Figure 7A). EAK proteins may also have non-
autonomous inhibitory effects on other cells that express
DAF-16/FoxO (Figure 7B). EAK regulation of DAF-16/FoxO
probably does not occur through DAF-9/CYP27A1, since daf-9
is epistatic to daf-16 for dauer arrest [64,65].
This work identiﬁes two membrane-associated PTP homo-
logs in the endocrine XXX cells that modulate insulin-like
signaling in C. elegans. In view of the striking structural and
functional similarities in insulin/IGF signaling among meta-
zoa, further studies of insulin/IGF signaling in C. elegans
should contribute to our understanding and management of
growth factor dysregulation in human disease.
Materials and Methods
eak mutant isolation, SNP mapping, and sequencing of mutant
alleles. akt-1(mg306) animals were mutagenized with ethyl methane-
sulfonate using standard procedures [92]. Four P0 animals were
placed on each of 100 6-cm NGM agar plates [93] and removed after
overnight egglay at 25 8C. F2 dauers were picked to new plates for
recovery after visualization under a Nikon SMZ800 dissecting
microscope. Recovered dauers were retested for the dauer phenotype
at 25 8C. Dauers that bred true were then outcrossed once with N2
(wild-type) animals and subjected to secondary assays. Mutants were
tested for suppression by feeding RNAi of daf-3/SMAD4 and daf-16/
FoxO as described [56]. Those that were suppressed by daf-16/FoxO
RNAi but not by daf-3/SMAD4 RNAi were outcrossed again, and F2
dauers were picked for recovery, singled for egglay, and picked to
worm lysis buffer containing 50 mM KCl, 10 mM Tris (pH 8.3), 2.5 mM
MgCl2, 0.45% NP-40, 0.45% Tween 20, 0.01% gelatin, and 60 lg/ml
proteinase K. After incubation at 70 8C for at least 10 min, 60 8C for
1 h, and 95 8C for 15 min, 2.5 ll of single worm lysate was PCR-
ampliﬁed in 100 mM Tris (pH 8.3), 500 mM KCl, 15 mM MgCl2, and
0.01% gelatin with Taq polymerase (Roche, Basel, Switzerland) using
primers ﬂanking the akt-1(mg306) point mutation. akt-1(mg306)
animals harbor a C-to-T transition at nucleotide 31730 of cosmid
C12D8 that creates a TaqI restriction fragment length polymorphism.
Mutants for which most or all F2 dauers were homozygous for akt-
1(mg306) were considered true Eak mutants and were analyzed
further. All mutants were outcrossed at least four times prior to
detailed phenotyping.
SNP mapping was performed essentially as described [67]. Mutants
were mated with the Hawaiian C. elegans isolate CB4856, and single F1
cross-progeny were allowed to lay eggs overnight at 25 8C. Individual
F2 dauers were picked for recovery, subjected to egglay, and picked to
100 ll of worm lysis buffer. Lysates were incubated as described
above. Then 2.5 ll of single worm lysate was PCR-ampliﬁed as
described above using genomic primers (Invitrogen, Carlsbad,
California, United States) spanning SNPs between CB4856 and the
wild-type N2 strain. SNPs were detected by restriction enzyme
digestion or sequencing of PCR products.
Genomic fragments corresponding to exons and predicted splice
junctions of eak-4, sdf-9, and eak-6 (WormBase Web site, http://www.
wormbase.org, release WS120, March 1, 2004) were ampliﬁed by PCR
and puriﬁed using the QIAquick PCR Puriﬁcation Kit (Qiagen,
Valencia, California, United State). Mutations were conﬁrmed by
sequencing both strands of DNA.
Dauer assays. Two or three gravid animals were picked to
individual 6-cm NGM plates, allowed to lay eggs for several hours,
and removed. Plates were shifted to the assay temperature, and
dauers were scored 48 to 60 h thereafter. All assays of 27 8C dauer
arrest were scored in blinded fashion.
RNAi. Feeding RNAi was performed as described [94], with minor
modiﬁcations. Six-well plates containing NGM agar þ 5 mM IPTG
were spotted with 400 ll of overnight cultures of E. coli HT115
harboring double-stranded RNAi expression plasmid L4440 [95] or
L4440 containing daf-12/NHR- or daf-16/FoxO-speciﬁc inserts. Over-
night cultures were grown in 2XYT medium containing 50 lg/ml
carbenicillin. After overnight incubation of RNAi plates at room
temperature (to allow IPTG induction of double-stranded RNA
synthesis), two L4 animals were picked to each well, grown at 15 8C,
removed after egglay, and shifted to 27 8C. Dauers were scored
approximately 60 h thereafter.
Life span assays. L4 animals were picked to seeded NGM agar
plates containing 0.1 mg/ml 5-ﬂuorodeoxyuridine (ten to 20 animals
per plate), incubated at 25 8C, and scored every 1 to 2 d for vitality as
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as dead and removed.
cDNA isolation. C. elegans total RNA was isolated as described [96].
cDNA was ampliﬁed from total RNA using the SuperScript III RT-
PCR Kit (Invitrogen). The 5’ and 3’ cDNA ends were identiﬁed using a
5’/3’ RACE kit (Roche). PCR products were cloned into pCR4-TOPO
(Invitrogen), and Qiaprep miniprep plasmid DNA (Qiagen) was
sequenced using primers ﬂanking the cloned insert.
RT-PCR of wild-type C. elegans total RNA revealed the presence of
two alternatively spliced eak-6 mRNAs differing by the absence or
presence of a single exon. The presence of the exon in the long cDNA
isoform, eak-6L, results in a 17-amino-acid in-frame insertion C-
terminal to the PTP domain of EAK-6 (Figure 2A). cDNA analysis also
revealed a GeneFinder misprediction in WormBase (WormBase web
site, http://www.wormbase.org, release WS120, March 1, 2004) of the
exon/intron boundary between exons 3 and 4 (unpublished data). The
5’ and 3’ RACE identiﬁed a 5’ cDNA end 13 nucleotides upstream of
the translation initiation codon and a 3’ cDNA end 303 nucleotides
downstream of the translation termination codon but did not
identify a trans-spliced SL1 leader (unpublished data).
GFP and RFP reporter constructs. For promoter fusion constructs,
promoter fragments were generated by amplifying 5’ upstream
sequences between the putative translational start codon and the
nearest boundary of the gene immediately upstream. The following
promoter fragments were ampliﬁed: eak-4p: nucleotides 13809 to
14696 of cosmid F53B2 [numbering corresponds to cosmid sequences
obtained from the National Center for Biotechnology Information
Web site (http://www.ncbi.nlm.nih.gov/)]; sdf-9p: nucleotides 10417 to
16170 of YAC Y44A6D; eak-6p: nucleotides 4381 to 5426 of cosmid
F10G8. PCR primers were tailed with BglII linkers. Promoter
fragments were puriﬁed using the Qiaquick PCR Puriﬁcation Kit
(Qiagen), digested with BglII, and repuriﬁed. eak-4 and eak-6 promoter
fragments were subcloned into BamHI-digested GFP reporter
plasmid pPD95.67 (a gift from Andrew Fire) to generate eak-4p::GFP
and eak-6p::GFP, respectively; the sdf-9 promoter fragment was
subcloned into BamHI-digested RFP [73] reporter plasmid
pPD95.75_mRFP3 (a gift from Ho Yi Mak) to generate sdf-9p::RFP.
Fragment orientation was conﬁrmed by restriction digestion.
Plasmids were puriﬁed using Qiagen columns.
Protein fusion constructs were made using overlap extension PCR
[97,98]. PCR fragments encompassing the putative promoter and
open reading frame up to but not including the translation
termination codon were fused to a PCR fragment containing GFP
and the unc-54 3’ untranslated region (ampliﬁed from the GFP
expression vector pPD95.75, a gift from Andrew Fire). The following
gene-speciﬁc fragments were ampliﬁed for protein fusions: EAK-4:
nucleotides 12780 to 14696 of cosmid F53B2; SDF-9: nucleotides
10417 to 18862 of YAC Y44A6D; EAK-6: nucleotides 4381 to 7152 of
cosmid F10G8. To construct the EAK-4::GFP G2A N-myristoylation
mutant, changes were made in the wild-type EAK-4::GFP primers to
encode a glycine-to-alanine missense mutation at amino acid 2 of
EAK-4. Fusion PCR products were puriﬁed using the Qiaquick PCR
Puriﬁcation Kit (Qiagen).
To generate transgenic animals, fusion constructs were coinjected
with 1.5–3ng/ll pha-1-rescuing plasmid pBX into pha-1(e2123) mutant
animals, and transgenic animals were selected and maintained by
growth at 25 8C [99]. Promoter and protein fusion constructs were
injected at approximately 50 ng/ll. In colocalization experiments, 50
ng/ll concentration of either eak-4p::GFP or eak-6p::GFP was coin-
jected with 50 ng/ll sdf-9p::RFP and 1.5 ng/ll pBX, transgenic lines
were established, and colocalization of GFP and RFP was assessed by
ﬂuorescence microscopy using a Zeiss Axioplan 2 microscope. In
subcellular localization experiments, EAK-4::GFP, SDF-9::GFP, and
EAK-6::GFP transgenic lines were established, a strain harboring an
integrated sdf-9p::RFP array was mated with each GFP strain, and F1
animals expressing both GFP and RFP were analyzed by ﬂuorescence
microscopy. To generate daf-2(e1370) animals harboring the SDF-
9::GFP array, daf-2(e1370) males were mated with pha-1(e2123) animals
carrying the SDF-9::GFP pha-1(þ) array, GFP(þ)F 1 cross-progeny were
isolated, and GFP(þ)F 2 dauers were picked after egglay and
incubation at 25 8C. Colocalization of DAF-16A::GFP and sdf-
9p::RFP was analyzed using a Zeiss LSM 510 confocal microscope
mounted on a Zeiss Axiovert 100M inverted microscope.
Rescue experiments. Cosmid rescue experiments were performed
by microinjection of cosmids or cosmid pools into eak-4(mg326);akt-
1(mg306) double mutant animals and assaying transgenic animals for
rescue of dauer formation at 25 8C. SUR-5::GFP was used as a
coinjection marker [100]. Cosmids were prepared using the Qiaprep
Miniprep Kit (Qiagen) and injected at concentrations of approx-
imately 1 to 10 lg/ml. Single gene rescue experiments were
performed with PCR fragments ampliﬁed from genomic DNA that
contained predicted promoter, open reading frame, and 3’ UTR
sequences for F53B2.3 (eak-4) and F10G8.4 (eak-6). Approximately 10
ng/ll of puriﬁed PCR product was coinjected with 100 ng/ll SUR-
5::GFP into eak-4(mg326);akt-1(mg306) or eak-6(mg329);akt-1(mg306)
mutant animals, and transgenic animals were assayed for rescue of
dauer arrest at 25 8C.
A construct containing the akt-1 gene under the control of the eak-
4 promoter was made using overlap extension PCR [97,98]. An eak-4
promoter fragment (nucleotides 13809 to 14696 of cosmid F53B2)
was fused to the akt-1 open reading frame and 3’ untranslated region
(nucleotides 30791 to 34802 of cosmid C12D8) to create eak-4p::AKT-
1. Approximately 10 ng/ll eak-4p::AKT-1 was coinjected with 100 ng/ll
SUR-5::GFP into eak-4(mg326);akt-1(mg306) mutant animals, and trans-
genic (GFP[þ]) animals from three independent lines were assayed for
rescue of dauer formation at 25 8C. Rescue phenotypes were
compared with those of nontransgenic (GFP[ ]) siblings.
Supporting Information
Figure S1. Pharyngeal Morphology and Alae in akt-1(mg306), eak, and
eak;akt-1 Dauers
daf-2(e1370), akt-1(mg306), eak-6(mg329), and eak-4(mg348);akt-1(mg306)
animals were grown at 25 8C (daf-2 and eak-4;akt-1) or 27 8C (akt-1 and
eak-6), and dauers were examined under Nomarski optics for
pharyngeal morphology and the presence of alae. The isthmus and
terminal bulb of the pharynx are denoted by arrows, and the alae are
denoted by arrowheads. All dauers examined had alae; however,
constriction of the isthmus and terminal bulb seen in daf-2 dauers
(top panel) is not observed in eak-6 or eak-4;akt-1 dauers (third and
bottom panels, respectively). akt-1 dauers exhibited an intermediate
degree of pharyngeal constriction (second panel). eak-4, sdf-9, akt-1 sdf-
9, and eak-6;akt-1 dauers had alae and exhibited pharyngeal
morphology comparable to eak-6 and eak-4;akt-1 dauers.
Found at DOI: 10.1371/journal.pgen.0020099.sg001 (2.9 MB PDF).
Figure S2. eak Interactions with Mutants in the DAF-2/InsR Signaling
Pathway
(A) eak mutants enhance the dauer arrest phenotype of age-1/PI3K and
pdk-1 loss-of-function mutants.
(B) eak mutants do not enhance the dauer arrest phenotype of an akt-2
loss-of-function mutant.
All error bars indicate standard deviation. All experiments were
performed twice. Refer to Table S1 for numbers of animals scored.
Found at DOI: 10.1371/journal.pgen.0020099.sg002 (826 KB PDF).
Figure S3. Epistasis Analysis of eak Mutants with Dauer-Defective daf-
2/InsR Pathway Mutants
(A) eak;akt-1 25 8C dauer arrest phenotypes are suppressed by a
mutation in daf-16/FoxO.
(B) eak 27 8C dauer phenotypes are suppressed by a weak loss-of-
function mutation in daf-18/PTEN.
(C) eak 27 8C dauer phenotypes are suppressed by a gain-of-function
mutation in akt-1. All error bars indicate standard deviation.
All experiments were performed twice. Refer to Table S1 for
numbers of animals scored.
Found at DOI: 10.1371/journal.pgen.0020099.sg003 (781 KB PDF).
Figure S4. akt-1, eak, and eak;akt-1 Mutants Have Normal Life Spans at
25 8C
This experiment was performed twice. Refer to Table S1 for numbers
of animals scored.
Found at DOI: 10.1371/journal.pgen.0020099.sg004 (553 KB PDF).
Figure S5. eak-4(mg348) Is a Null Allele
eak-4(mg348) males were mated with BC1216 (sDf21/nT1; þ/nT1)
hermaphrodites, and F1 cross-progeny were scored for dauer arrest
at 27 8C. sDf21 is a deﬁciency on chromosome IV that deletes eak-4.
(A) F1 cross-progeny from eak-4(mg348) X BC1216 do not show
enhanced dauer arrest at 27 8C compared to eak-4(mg348).
(B) Comparison of observed to expected embryonic lethality among
progeny conﬁrms the identity of the BC1216 strain.
Found at DOI: 10.1371/journal.pgen.0020099.sg005 (630 KB PDF).
Figure S6. Plasma Membrane Localization of SDF-9::GFP Does Not
Require Wild-type DAF-2/InsR Function
daf-2 wild-type and daf-2(e1370) L1 animals harboring an SDF-9::GFP
PLoS Genetics | www.plosgenetics.org July 2006 | Volume 2 | Issue 7 | e99 0941
PTP Homologs Potentiate Akt Signalingtranslational fusion construct were grown at 25 8C and analyzed using
ﬂuorescence microscopy.
Found at DOI: 10.1371/journal.pgen.0020099.sg006 (558 KB PDF).
Table S1. Numbers of Animals Assayed
Found at DOI: 10.1371/journal.pgen.0020099.st001 (15 KB XLS).
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